¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2033³â)
Global Multiple Myeloma Therapeutics Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
»óǰÄÚµå : 1676226
¸®¼­Ä¡»ç : Value Market Research
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 107 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,920 £Ü 5,671,000
PDF & Excel (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,730 £Ü 6,843,000
PDF & Excel (10-user License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,430 £Ü 10,750,000
PDF & Excel (Corporate User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÀüÀÚÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 329¾ï 6,000¸¸ ´Þ·¯¿¡¼­ 2033³â 610¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2026-2033³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 7.09%ÀÇ °ß°íÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº ´Ù¹ß¼º°ñ¼öÁ¾ À¯º´·ü Áõ°¡¿Í Ä¡·á ¿É¼ÇÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ´Ù¹ß¼º °ñ¼öÁ¾Àº °ñ¼ö¿¡¼­ ºñÁ¤»óÀûÀÎ ÇüÁú¼¼Æ÷ÀÇ Áõ½ÄÀ» Ư¡À¸·Î ÇÏ´Â Ç÷¾×¾ÏÀÇ ÀÏÁ¾À¸·Î, Áø´Ü ¹× °ü¸® Ãø¸é¿¡¼­ Å« ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀÌ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥ ´ÜŬ·ÐÇ×ü, ÇÁ·ÎÅ×¾ÆÁ» ¾ïÁ¦Á¦, ¸é¿ªÁ¶ÀýÁ¦ µî Çõ½ÅÀûÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·áÀÇ Á߿伺ÀÌ °­Á¶µÇ¸é¼­ ÀÓ»óÀǵéÀº ȯÀÚ °³°³ÀÎÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á ¿ä¹ýÀ» Ãß±¸Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ½ÃÀåÀº ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå Çü¼º¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº Ä¡·á È¿°ú¿Í ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í, CAR T ¼¼Æ÷ Ä¡·á¿Í ÀÌÁß Æ¯À̼º Ç×üÀÇ ÃâÇöÀº ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ÀÇ »õ·Î¿î ¿µ¿ªÀ¸·Î Àç¹ß¼º ¶Ç´Â ³­Ä¡¼º ȯÀÚ¿¡°Ô À¯¸ÁÇÑ °á°ú¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. À¯¸ÁÇÑ °á°ú¸¦ °¡Á®¿É´Ï´Ù. ¶ÇÇÑ, µ¿¹Ý Áø´Ü ¾à¹°ÀÇ ÅëÇÕÀ» ÅëÇØ ÀÇ·áÁøÀº ƯÁ¤ Ä¡·á°¡ °¡Àå È¿°úÀûÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ȯÀÚ¸¦ ½Äº°ÇÒ ¼ö ÀÖ°Ô µÇ¾î Ä¡·á °á°ú¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¿¬±¸°³¹ßÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í Ä¡·áÁ¦¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÌ °æÀï¿¡¼­ ¿ìÀ§¸¦ Á¡ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¶ÇÇÑ, ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº ±ÔÁ¦ ¹ßÀü°ú »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ÀÓ»óÀû °ËÁõÀÇ Çʿ伺¿¡ ÀÇÇØ Á¡Á¡ ´õ ¸¹Àº ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇ·á½Ã½ºÅÛÀÌ ±Ù°ÅÁß½ÉÀÇ Áø·á¸¦ äÅÃÇÔ¿¡ µû¶ó ¾ö°ÝÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇÑ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â »õ·Î¿î Ä¡·á¹ý Á¶ÇÕÀ» Ž»öÇÏ°í ±âÁ¸ Ä¡·á¹ýÀ» °³¼±Çϱâ À§ÇÑ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Ä¡·á °áÁ¤¿¡ ÀÖ¾î »îÀÇ Áú¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ÀÇ È¯°æÀÌ º¯È­Çϰí ÀÖ½À´Ï´Ù. Á¦Ç° °³¹ßÀ» ÀÓ»óÀû ¿ä±¸¿Í ÀÏÄ¡½Ã۰í ȯÀÚÀÇ Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â ¼Ö·ç¼ÇÀÇ °¡Ä¡¸¦ ÀÔÁõÇÏ´Â ±â¾÷µéÀº ÀÌ ¿ªµ¿ÀûÀÎ ½ÃÀå¿¡¼­ ¼º°øÇÒ ¼ö ÀÖ´Â ÁÁÀº À§Ä¡¿¡ ¼­°Ô µÉ °ÍÀÔ´Ï´Ù.

´ç»çÀÇ º¸°í¼­´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷ ¹× ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÌ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇϱâ À§ÇØ ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼­´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇØ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä: ½ÃÀå °³¿ä: Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲÀ» Æ÷ÇÔÇÑ »ó¼¼ÇÑ ½ÃÀå ¼Ò°³.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ: ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼­´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È­, »õ·Î¿î Æ®·»µå µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.

¼¼ºÐÈ­ ºÐ¼® : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÀï»óȲ: ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, À繫½ÇÀû µî ÁÖ¿ä ½ÃÀå ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ °íÂûÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ µ¿¾È ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ¹Ì·¡ ½ÃÀå ±ËÀûÀ» ³ªÅ¸³»´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.

Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

»õ·Î¿î Æ®·»µå¿Í ±âȸ: ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÎ¹®À» ½Äº°ÇÕ´Ï´Ù. ¹Ì·¡ ½ÃÀå °³Ã´ ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ »ê¾÷ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

Á¦7Àå ¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Áúȯ À¯Çüº°

Á¦8Àå ¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·áÁ¦ ±â¾÷ °æÀï ±¸µµ

Á¦11Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multiple Myeloma Therapeutics Market size is anticipated to grow from USD 32.96 Billion in 2024 to USD 61.07 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.09% during the forecast period of 2026 to 2033.

The Multiple Myeloma Therapeutics market is experiencing robust growth, driven by the increasing incidence of multiple myeloma and the ongoing advancements in treatment options. Multiple myeloma, a type of blood cancer characterized by the proliferation of abnormal plasma cells in the bone marrow, presents significant challenges in terms of diagnosis and management. As healthcare providers seek to improve patient outcomes, the demand for innovative therapeutics, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs, is surging. The growing emphasis on personalized medicine and targeted therapies is further propelling the market, as clinicians aim to tailor treatment regimens to individual patient profiles.

Technological advancements are playing a pivotal role in shaping the Multiple Myeloma Therapeutics market, with innovations in drug development and delivery systems enhancing treatment efficacy and safety. The emergence of CAR T-cell therapy and bispecific antibodies represents a new frontier in multiple myeloma treatment, offering promising results for patients with relapsed or refractory disease. Additionally, the integration of companion diagnostics is enabling healthcare providers to identify patients who are most likely to benefit from specific therapies, thereby optimizing treatment outcomes. As the market continues to evolve, companies that prioritize research and development to advance their therapeutic offerings will likely gain a competitive edge.

Moreover, the Multiple Myeloma Therapeutics market is increasingly influenced by regulatory developments and the need for clinical validation of new therapies. As healthcare systems adopt evidence-based practices, the demand for therapeutics that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel treatment combinations and improving existing therapies. Furthermore, the growing focus on patient-centric care and the importance of quality of life in treatment decisions are shaping the landscape of multiple myeloma therapeutics. Companies that align their product development with clinical needs and demonstrate the value of their solutions in improving patient outcomes will be well-positioned to thrive in this dynamic market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Treatment Type

By Route Of Administration

By Disease Type

By End-Use

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. MULTIPLE MYELOMA THERAPEUTICS INDUSTRY ANALYSIS

4. VALUE CHAIN ANALYSIS

5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY TREATMENT TYPE

6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY END-USE

9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

10. COMPETITIVE LANDSCAPE OF THE MULTIPLE MYELOMA THERAPEUTICS COMPANIES

11. COMPANY PROFILES OF MULTIPLE MYELOMA THERAPEUTICS INDUSTRY

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â